Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.
Try us for 14 days
Try a trial subscription for access to our quality journalism
ALK boss on deficit: Investments in the future require short-term costs
The revenue of Danish allergy group ALK has increased to approximately DKK 3 billion (USD 460 million), however, the bottom line and EBIT remain negative. Despite red numbers, ALK increase investments in the coming year. "ALK is a growth case, and it also entails short-term costs," says the CEO.
